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Abstract
IMPORTANCE Most patients with primary aldosteronism, a major cause of secondary hypertension,
are not identified or appropriately treated because of difficulties in diagnosis and subtype
classification. Applications of artificial intelligence combined with mass spectrometry–based steroid
profiling could address this problem.
OBJECTIVE To assess whether plasma steroid profiling combined with machine learning might
facilitate diagnosis and treatment stratification of primary aldosteronism, particularly for patients
with unilateral adenomas due to KCNJ5 sequence variants.
DESIGN, SETTING, AND PARTICIPANTS This diagnostic study was conducted at multiple tertiary
care referral centers. Steroid profiles were measured from June 2013 to March 2017 in 462 patients
tested for primary aldosteronism and 201 patients with hypertension. Data analyses were performed
from September 2018 to August 2019.
MAIN OUTCOMES AND MEASURES The aldosterone to renin ratio and saline infusion tests were
used to diagnose primary aldosteronism. Subtyping was done by adrenal venous sampling and
follow-up of patients who underwent adrenalectomy. Statistical tests and machine-learning
algorithms were applied to plasma steroid profiles. Areas under receiver operating characteristic
curves, sensitivity, specificity, and other diagnostic performance measures were calculated.
RESULTS Primary aldosteronism was confirmed in 273 patients (165 men [60%]; mean [SD] age, 51
[10] years), including 134 with bilateral disease and 139 with unilateral adenomas (58 with and 81
without somatic KCNJ5 sequence variants). Plasma steroid profiles varied according to disease
subtype and were particularly distinctive in patients with adenomas due to KCNJ5 sequence variants,
who showed better rates of biochemical cure after adrenalectomy than other patients. Among
patients tested for primary aldosteronism, a selection of 8 steroids in combination with the
aldosterone to renin ratio showed improved effectiveness for diagnosis over either strategy alone. In
contrast, the steroid profile alone showed superior performance over the aldosterone to renin ratio
for identifying unilateral disease, particularly adenomas due to KCNJ5 sequence variants. Among 632
patients included in the analysis, machine learning–designed combinatorial marker profiles of 7
steroids alone both predicted primary aldosteronism in 1 step and subtyped patients with unilateral
adenomas due to KCNJ5 sequence variants at diagnostic sensitivities of 69% (95% CI, 68%-71%) and
85% (95% CI, 81%-88%), respectively, and at specificities of 94% (95% CI, 93%-94%) and 97%
(95% CI, 97%-98%), respectively. The validation series yielded comparable diagnostic performance.
CONCLUSIONS AND RELEVANCE Machine learning–designed combinatorial plasma steroid profiles
may facilitate both screening for primary aldosteronism and identification of patients with unilateral
(continued)
Key Points
Question Does steroid profiling
combined with machine learning offer a
potential 1-step strategy to facilitate
diagnosis and subtype classification for
treatment stratification of patients with
primary aldosteronism?
Findings This diagnostic study
involving patients tested for primary
aldosteronism found that those with
unilateral adenomas harboring KCNJ5
sequence variants showed the most
clinical benefit from surgical
intervention and could be effectively
identified at a single screening step
using machine-learning combinatorial
marker profiles of 7 steroids.
Meaning The outlined strategy offers a
potential approach to improve diagnosis
of primary aldosteronism and facilitate
more efficient and effective
stratification of patients for surgical
intervention.
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Abstract (continued)
adenomas due to KCNJ5 sequence variants, who are most likely to show benefit from surgical
intervention.
JAMA Network Open. 2020;3(9):e2016209. doi:10.1001/jamanetworkopen.2020.16209
Introduction
Applications of artificial intelligence, including machine learning, are gaining increasing recognition
for informing medical decision-making.1-4 Machine learning may be particularly useful in
heterogeneous disorders where there is a need for stratification to guide therapy.5-8 One such
disorder is primary aldosteronism (PA), a common cause of secondary hypertension with 2 main
subtypes for which treatment stratification is crucial but difficult.9,10 With a prevalence of 5% to 7%
among unselected patients with hypertension and up to 20% among patients with severe
hypertension, PA affects large numbers of patients and is associated with considerable morbidity
exceeding that of patients with primary hypertension (PHT) and similar elevations of blood
pressure.11,12
The aforementioned considerations highlight the importance of effective methods for diagnosis
and treatment of PA, which must allow for stratification according to unilateral vs bilateral
hypersecretion of aldosterone.9,10 Cure of the former can be achieved by adrenalectomy, whereas
mineralocorticoid receptor antagonists are indicated for the bilateral subtype. Attaining this
stratification is not simple and usually requires adrenal venous sampling (AVS), a technically
demanding, expensive, time-consuming, and not infallible procedure.9,13-16 In 2 independent
studies,13,16 discordant lateralization results were observed in 24% to 28% of patients who
underwent AVS with vs without adrenocorticotropin. In another study,14 clinical outcomes did not
differ according to determination of unilateral disease by AVS vs radiological imaging. In a fourth
study,15 there were no significant differences in rates of biochemical cure (76% vs 69%) in patients
younger than 65 years who underwent adrenalectomy according to AVS lateralization ratios larger vs
smaller than 4.
Apart from the difficulties and limited effectiveness of AVS for subtype classification, there are
also problems with earlier steps in the diagnosis of PA. Although the aldosterone to renin ratio (ARR)
offers a time-honored method for screening, there is considerable overlap of ratios among patients
with and without PA17,18; thus, at ARR cutoffs selected to optimize diagnostic sensitivity, there are
many false-positives, leading to the need for confirmatory studies.19,20 Such multiple steps, poor
standardization, requirements to consider antihypertensive medications, and difficulties with AVS all
represent barriers to diagnostic stratification; consequently, most patients remain undiagnosed and
are not appropriately treated.9,21 Improved approaches for diagnostic stratification are
therefore needed.
With the aforementioned considerations in mind, we examined the use of mass spectrometry–
based steroid profiling combined with machine learning for diagnostic stratification, with the
hypothesis that this approach at screening might facilitate case detection and also allow for subtype
classification. This hypothesis was based on findings that distinct steroid profiles in adrenal venous
plasma of patients with bilateral and unilateral PA translated to similarly distinct profiles in peripheral
plasma.22 Patients with unilateral aldosterone-producing adenomas (APAs) due to somatic sequence
variants of KCNJ5 have particularly distinct steroid profiles.23 These patients also have larger and
more clearly visualized APAs and show the most favorable outcomes after adrenalectomy.24-27 The
use of steroid profiles to identify these patients may, therefore, be especially useful. Thus, the
primary objective of this study was to establish whether steroid profiling could facilitate both
identification and subtype classification of patients with PA, particularly those with unilateral APAs
due to KCNJ5 sequence variants.
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Methods
Patients
This diagnostic study was approved by the Klinikum der Ludwig-Maximilians-Universität München,
University of Turin, Technische Universität Dresden, and Institute of Cardiology (Warsaw). The study
follows the Standards for Reporting of Diagnostic Accuracy (STARD) reporting guideline. All patients
provided written informed consent under protocols approved by ethics committees at the 4 tertiary
clinical care centers where patients were referred for testing.
The study involved mass spectrometry–based steroid profiling of plasma specimens from 462
patients tested for primary aldosteronism between June 13, 2013, and March 8, 2017. Follow-up of
patients was completed by July 31, 2018. Patient data and specimens were derived from studies and
registries with a focus on hypertension and PA, including the Conn registry in Germany, the European
Network for Studies of Adrenal Tumors registry, and the Prospective Monoamine-Producing
Tumor study.
Patients were tested for PA according to 1 or more of several criteria: office blood pressure
greater than 150/100 mm Hg, therapy-resistant hypertension, or hypertension associated with
hypokalemia or hemorrhagic stroke, an adrenal incidentaloma, or obstructive sleep apnea. Other
forms of secondary hypertension were excluded when relevant. Testing for PA followed standard
practice guidelines,28 including use of the ARR, confirmatory testing, and AVS to distinguish
unilateral from bilateral PA (eAppendix 1 in the Supplement).
PA was confirmed in 304 patients included into the study according to selective sampling of
both adrenal veins or in whom adrenalectomies were performed without AVS because of young age
and imaging evidence of a single adrenal adenoma (eFigure 1 in the Supplement). Among these
patients, 116 were defined by AVS to have bilateral disease. After exclusions among the others with
unilateral disease, there remained 157 patients for whom Sanger sequencing for somatic sequence
variants of KCNJ5 was performed in resected tumor specimens (eAppendix 1 in the Supplement). Two
and 16 of the respective 60 and 97 patients with and without KCNJ5 sequence variants did not
experience complete biochemical cure and were reassigned as having bilateral PA according to the
primary aldosteronism surgical outcome (PASO) classification system.29 PA was excluded in 158
patients, who were subsequently defined to have PHT. A further 201 patients with hypertension
from a reference population30 were included to enhance patient numbers for generation of machine-
learning algorithms (eTable 1 in the Supplement).
Steroid Profiling
Steroid profiling was performed using liquid chromatography with tandem mass spectrometry,31
with details outlined in eAppendix 1 and eTable 2 in the Supplement. Measurements included 15
adrenal steroids: aldosterone, 18-oxocortisol, 18-hydroxycortisol, cortisol, cortisone,
11-deoxycortisol, 21-deoxycortisol, corticosterone, 11-deoxycorticosterone, progesterone,
17-hydroxyprogesterone, pregnenolone, androstenedione, dehydroepiandrosterone, and
dehydroepiandrosterone-sulfate. Reference intervals were established as discussed elsewhere
(eTable 3 in the Supplement).30
Statistical Analysis
Statistical analyses used JMP Pro statistical software version 14 (SAS Institute). Unless otherwise
specified, significance was defined as P < .05. Statistical tests were 2-tailed and included Fisher exact
test and the Mann-Whitney U test. Nominal logistic modeling was used to assess for associations of
the presence versus absence of a KCNJ5 sequence variant with PASO criteria based–outcomes
according to sex and age as additional covariates. Associations are shown according to whole model
and likelihood ratio tests. Data for steroids were normalized by logarithmic transformation before
analyses, including for generation of geometric means and 95% CIs. Least-squares multivariable
models were used to assess differences in plasma steroids according to patient group, age, sex, and
JAMA Network Open | Pathology and Laboratory Medicine Steroid Profiling and Machine Learning for Diagnosing Primary Aldosteronism
JAMA Network Open. 2020;3(9):e2016209. doi:10.1001/jamanetworkopen.2020.16209 (Reprinted) September 29, 2020 3/14
jamanetwork/2020/jno/09_29_2020/zoi200603 PAGE: 3 SESS: 28 OUTPUT: Sep 9 7:49 2020
assay batch. Differences among patient groups were assessed using the Tukey honest significance
test. Logistic regression was used to generate receiver operating characteristic curves, with
selections of steroids in profiles based on both stepwise regression and likelihood ratios for each
steroid. Differences between areas under receiver operating characteristic curves (AUROCs) and
data from confusion matrices were used to assess performance of logistic regression models. Data
were normalized according to upper cutoffs of reference intervals, which for most of the plasma
steroids were specific for either or both age and sex (eTable 3 in the Supplement). Data analyses were
performed from September 2018 to August 2019.
Machine Learning
In brief, the machine-learning workflow involved 3 phases (eFigure 2 in the Supplement): data
preparation, model learning, and external validation. Data preparation included several procedures
for normalization, batch correction, and, in some models, adjustments for age and sex (see eTable 3,
eTable 4, and eTable 5 in the Supplement). At this stage, each of the 13 different data sets was
subdivided into 2 different proportions for learning and external validation data sets, as outlined in
eAppendix 1 in the Supplement. After data preparation, machine-learning tasks for feature selection,
model training, and sample classification in the second model learning phase were performed
according to different algorithms, with their application in this phase restricted to learning data sets.
Feature selection involved the use of 4 different algorithms to identify specific steroid combinations
that provided either optimal segregation of patients with and without PA or identification of those
with unilateral disease due to KCNJ5 sequence variants among all patients.
Several combinations of the aforementioned procedures were investigated for optimized data
analysis and assessed according to 9 machine-learning algorithms corresponding to variations of 4
commonly used models in medicine: random forest (RF), support vector machine (SVM), linear
discriminant analysis, and logistic regression. A total of 585 models arising from 13 data sets and 9
machine-learning algorithms were tested, each involving a 10 times, 5-fold cross-validation step
(eFigure 3 in the Supplement). Optimal classification, determined as part of the final validation phase
according to either AUROC or F scores, was determined according to external validations achieved
by application of algorithms for each of the 585 models to external validation data sets.
Results
Final Study Population
PA was confirmed in 273 patients (165 men [60%]; mean [SD] age, 51 [10] years). In addition to the
201 patients of the reference hypertension population, after screening and subtype classification,
there were 158 patients classified with PHT (134 with bilateral PA and 139 with unilateral PA) (eTable 1
in the Supplement). Among those with unilateral PA, 58 had APAs with KCNJ5 sequence variants and
81 did not and were designated as having wild-type KCNJ5.
Genotype-Related Therapeutic Outcomes and Patient Group Reclassification
Among patients who underwent adrenalectomy because of presumed unilateral PA, those with APAs
with KCNJ5 sequence variants were, on average, 5.8 years younger (mean [SD] age, 47.4 [10.8] years
vs 51.3 [10.3] years) and were 2.7-fold more likely to be female (47 women [78.3%] vs 28 women
[28.9%]) compared with those with wild-type KCNJ5 APAs (Table 1). According to the PASO
classification, the presence of KCNJ5 sequence variants conferred significantly better clinical and
biochemical outcomes after adrenalectomy compared with the absence of KCNJ5 sequence variants.
However, logistic modeling indicated that improved blood pressure control in patients with variant
vs wild-type KCNJ5 APAs was accounted for by the younger age and female predominance of patients
with KCNJ5 sequence variants. In contrast, the presence of a KCNJ5 sequence variant remained
independently associated with biochemical cure. The overall postadrenalectomy biochemical cure
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rate in this study was 88.5%; the cure rates were 96.6% for patients with KCNJ5 sequence variants
and 83.6% for patients without KCNJ5 sequence variants.
Steroid Profiles
With least squares adjustments of sex, age, and assay batch, all plasma steroids showed some
differences among the 5 patient groups (eTable 4 in the Supplement). Plasma 18-oxocortisol showed
differences among all groups but especially the group with unilateral APAs due to KCNJ5 sequence
variants, in whom plasma concentrations were 6.2- to 10.3-fold higher than all other groups
(Table 2). Plasma 18-hydroxycortisol in the variant KCNJ5 group was also 3.3- to 4.0-fold higher than
in other groups. Plasma aldosterone in the 2 unilateral disease groups, which did not differ, were
higher than in the other 3 groups. Other steroids were either similarly increased in patients with PA
Table 1. Comparisons of Age, Sex, and Primary Aldosteronism Surgical Outcome Clinical and Biochemical
Outcomes in Patients With Adrenal Venous Sampling–Lateralized Evidence of Unilateral Adrenal Aldosterone








Age, mean (SD), y 53.1 (10.3) 47.4 (10.8) .002
Sex
Female 28 (28.9) 47 (78.3)
<.001
Male 69 (71.1) 13 (27.7)
Clinical outcomes of primary aldosteronism surgerya
Complete cure 20 (20.6) 24 (40.0)
.008Partial cure 52 (53.6) 30 (50.0)
Failure 25 (25.8) 6 (10.0)
Biochemical outcomes of primary adolsteronism surgeryb
Complete cure 81 (83.6) 58 (96.6)
.04Partial cure 7 (7.2) 1 (1.7)
Failure 9 (9.2) 1 (1.7)
a In the multivariate analyses for clinical outcomes,
likelihood ratios were 9.34 for age impact (P = .009),
6.01 for sex impact (P = .05), and 1.42 for KCNJ5
impact (P = .49), with P < .001 for the whole model.
b In the multivariate analyses for biochemical
outcomes, likelihood ratios were 9.15 for age impact
(P = .01), 0.34 for sex impact (P = .85), and 7.16 for
KCNJ5 impact (P = .03), with P = .01 for the
whole model.
Table 2. Plasma Concentrations of Steroids in Reference Patients With Hypertension, Patients With Primary Hypertension, and Patients with Bilateral Primary
Aldosteronism or Unilateral Primary Aldosteronism Without and With KCNJ5 Sequence Variants
Steroid




KCNJ5 Unilateral with variant KCNJ5
Aldosterone 0.091 (0.077-0.106) 0.143 (0.119-0.169) 0.260 (0.222-0.302) 0.384 (0.312-0.463) 0.436 (0.341-0.543)
18-Oxocortisol 0.026 (0.022-0.031) 0.043 (0.035-0.052) 0.056 (0.047-0.066) 0.093 (0.074-0.114) 0.578 (0.440-0.735)
18-Hydroxycortisol 1.62 (1.41-1.84) 1.74 (1.50-1.99) 1.75 (1.54-1.97) 2.11 (1.79-2.46) 6.960 (5.71-8.34)
Corticosterone 4.28 (3.60-5.01) 5.50 (4.57-6.53) 7.21 (6.13-8.39) 6.36 (5.15-7.70) 7.11 (5.52-8.90)
11-Deoxycorticosterone 0.063 (0.052-0.075) 0.112 (0.091-0.135) 0.162 (0.136-0.191) 0.277 (0.220-0.342) 0.311 (0.235-0.397)
11-Deoxycortisol 1.332 (1.074-1.618) 1.610 (1.275-1.985) 2.935 (2.397-3.529) 4.500 (3.455-5.686) 2.917 (2.124-3.838)
21-Deoxycortisol 0.039 (0.030-0.050) 0.044 (0.032-0.057) 0.078 (0.060-0.099) 0.083 (0.059-0.111) 0.085 (0.056-0.120)
Cortisol 237 (213-262) 332 (296-370) 327 (296-360) 248 (218-280) 274 (235-317)
Cortisone 47.2 (43.2-51.4) 53.2 (48.3-58.4) 48.4 (44.5-52.5) 35.5 (31.8-39.4) 43.4 (38.2-49.1)
Androstenedione 2.47 (2.25-2.70) 2.69 (2.43-2.96) 3.48 (3.19-3.79) 2.87 (2.56-3.19) 3.16 (2.76-3.58)
Dehydroepiandrosterone 8.70 (7.66-9.81) 7.91 (6.89-8.99) 7.90 (7.01-8.85) 6.19 (5.30-7.15) 7.97 (6.63-9.45)
Dehydroepiandrosterone-sulfate 3401 (3061-3758) 2805 (2504-3125) 2718 (2461-2987) 2234 (1965-2520) 2506 (2151-2888)
17-Hydroxyprogesterone 1.10 (0.96-1.24) 1.39 (1.20-1.59) 2.07 (1.83-2.33) 1.95 (1.65-2.27) 2.05 (1.68-2.45)
Progesterone 0.336 (0.269-0.411) 0.277 (0.217-0.344) 0.595 (0.483-0.720) 0.577 (0.438-0.735) 0.431 (0.310-0.572)
Pregnenolone 1.95 (1.61-2.32) 2.12 (1.73-2.56) 1.51 (1.26-1.78) 2.09 (1.66-2.58) 2.30 (1.74-2.94)
a Geometric means and 95% CIs were derived from the exponents of logarithmically transformed data. For whole model differences, see eTable 4 in the Supplement.
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or showed differing patterns or decreases or increases compared with patients with hypertension
according to the particular subtype of PA.
Diagnostic Test Performance of the ARR and Plasma Steroids
From differences in AUROCs, a selected panel of 8 steroids was less effective than the ARR
(difference in AUROC, 0.053; 95% CI, 0.006 to 0.099; P = .03) for differentiating patients with PA
from those with hypertension, but more effective (difference in AUROC, 0.107; 95% CI, 0.037 to
0.176; P = .003) for distinguishing the unilateral variant KCNJ5 APA group from others (Figure 1).
Combination of the steroid profile with the ARR was nevertheless more effective for discriminating
Figure 1. Areas Under the Receiver Operating Characteristic Curves (AUROCs) Comparing the Aldosterone to



















































Unilateral primary aldosteronism with KCNJ5 variantB































































Unilateral primary aldosteronism with KCNJ5 wild typeD












Each of the 4 panels represents a comparison of
AUROCs for the single indicated patient group with the
other 3 groups combined. Thus, AUROCs for primary
hypertension illustrate the diagnostic performance for
distinguishing all patients with primary aldosteronism
from primary hypertension, but with sensitivity
illustrative for detection of primary hypertension. The




JAMA Network Open | Pathology and Laboratory Medicine Steroid Profiling and Machine Learning for Diagnosing Primary Aldosteronism
JAMA Network Open. 2020;3(9):e2016209. doi:10.1001/jamanetworkopen.2020.16209 (Reprinted) September 29, 2020 6/14
jamanetwork/2020/jno/09_29_2020/zoi200603 PAGE: 6 SESS: 28 OUTPUT: Sep 9 7:49 2020
PA from PHT than use of either the steroid profile (difference in AUROC, 0.089; 95% CI, 0.059 to
0.119; P < .001) or the ARR (difference in AUROC, 0.036; 95% CI, 0.013 to 0.060; P = .003) alone.
Combination of the steroid profile with the ARR improved performance over the ARR alone for
distinguishing the KCNJ5 sequence variant group from other groups (difference in AUROC, 0.134;
95% CI, 0.082 to 0.186; P < .001), but not the steroid profile alone (difference in AUROC, 0.027; 95%
CI, −0.004 to 0.016; P = .08). Similar results were also observed for the unilateral wild-type KCNJ5
group, but for both this group and the bilateral PA group, all AUROCs were lower than for PHT and
unilateral KCNJ5 sequence variant groups.
From confusion matrices, steroid profiles correctly identified nearly 3 times more patients with
variant KCNJ5 unilateral disease than the ARR (eTable 6 in the Supplement). With the addition of the
steroid profile to the ARR, the diagnostic yield of patients correctly identified with PA increased from
69.6% (95% CI, 64.2%-75.0%) to 81.3% (95% CI, 76.7%-85.9%) at respective diagnostic
specificities of 89.2% (95% CI, 84.3%-94.1%) and 89.9% (95% CI, 85.2%-94.6%).
Steroid Profiling With Machine Learning
After batch corrections (eFigure 4 and eFigure 5 in the Supplement) and using feature selection
within machine-learning approaches, combinatorial markers composed of up to 7 steroids were
identified that offered best performance for discriminating patient groups (eFigure 5, eFigure 6,
eFigure 7, eFigure 8, eFigure 9, and eFigure 10 in the Supplement). Among those steroids,
aldosterone, 18-oxocortisol, and 18-hydroxycortisol commonly occupied the top 3 places for
discriminatory power. The next steroid with useful discriminatory power was 11-deoxycorticosterone,
followed by several others depending on the model.
The final selection of models for optimal classification was reduced to 21 best models according
to either AUROCs or F scores (eTable 7 in the Supplement). Among these, an RF model provided
optimal performance for the classification of patients with and without PA, whereas a nonlinear
(radial basis function kernel) SVM model was optimal for patients with unilateral variant KCNJ5 APAs
(Figure 2). For both models, aldosterone, 18-oxocortisol, and 18-hydroxycortisol occupied the top
3 places, with 11-deoxycorticosterone following in fourth and fifth places, respectively, for the SVM
and RF models. For the SVM model, cortisone, 11-deoxycortisol, and androstenedione replaced
Figure 2. Results for the 2 Best Machine-Learning Models
Random forest model representationA Support vector machine model representationB
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Panels A and C show a random forest (RF) model for
the differentiation of primary hypertension (HT) from
primary aldosteronism. Panels B and D show a support
vector machine (SVM) with a nonlinear kernel model
for the differentiation of unilateral KCNJ5 sequence
variants in primary aldosteronism vs other groups.
Panel A shows the subtree from 1 decision tree of 500
in the model representing how random forest predicts
new samples. Panel B outlines the mathematical
formula used in SVM to predict new sample scores,
where k is the number of binary SVM models created
for the 1 vs 1 approach for multiclass SVM training, x is
the new sample to be predicted, n is the number of
support vectors for the kth binary SVM, α and b are the
parameters learned from the training step of the kth
binary SVM, γ is the class of the respective kth support
vector (1 or −1), and G(Χk,j,Χ) is the dot product
between the jth support vector hyperplane measures
in the binary SVM k with the (new) sample
measurements x. Correlation networks from the
respective selected features for each model are shown
in panels C and D, with nodes in brown showing
common features. DHEA indicates
dehydroepiandrosterone.
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corticosterone, 17-hydroxyprogesterone, and dehydroepiandrosterone as selected features of the
RF model.
Performance of RF and SVM models upon external validation was similar or even appeared to
exceed that of the learning series (Table 3), according to 10 cross-validations in 5-folds (eAppendix 2
and eFigure 2 in the Supplement). Comparisons of AUROCs and F scores indicated that the SVM
model performed nearly as well as the RF model for identifying patients with PA, but was consistently
better for identifying those with variant KCNJ5 APAs. Using the RF model to identify patients with
PA, among all 632 patients, diagnostic sensitivity in the learning series was 69% (95% CI, 68%-71%)
and specificity was 94% (95% CI, 93%-94%). The external validation series yielded sensitivity of
85% and specificity of 100%. To identify patients with variant KCNJ5 APAs, the SVM model yielded a
diagnostic sensitivity of 85% (95% CI, 81%-88%) at a specificity of 97% (95% CI, 97%-98%). The
external validation series yielded respective values of sensitivity of 100% and specificity of 98%.
As outlined in eAppendix 2 in the Supplement, the aforementioned measures of diagnostic
performance were derived using learning ratios of 90% optimal for training and testing (thus, 10%
Table 3. Confusion Matrices and Diagnostic Performance for the 2 Machine-Learning Models (RF-Gini and SVMnl-RFE) for the Learning (Training and Testing) and











PHT 60.4 2.4 1.2 0.6 36 0 0 0
B-PA 9 11 2.9 1.2 3 6 3 1
Wild-type KCNJ5 4.1 5.4 3.4 1.7 1 4 3 0
Variant KCNJ5 2 1.7 2 4.6 0 0 1 5
Diagnostic
performancec
Sensitivity, % 94 (93-94) 42 (40-45) 26 (24-29) 46 (42-49) 100 46 38 83
Specificity, % 69 (68-71) 89 (89-90) 94 (94-95) 97 (96-97) 85 92 93 98
AUROC 0.815 (0.807-0.825) 0.657 (0.645-0.670) 0.599 (0.585-0.613) 0.714 (0.690-0.730) 0.926 0.691 0.651 0.908
PPV, % 80 (79-81) 52 (50-55) 38 (32-40) 59 (55-64) 90 60 43 83
NPV, % 89 (88-90) 86 (85-87) 90 (89-91) 95 (94-95) 100 87 91 98
F score 0.863 (0.858-0.870) 0.464 (0.440-0.480) 0.309 (0.279-0.336) 0.516 (0.484-0.548) 0.947 0.522 0.400 0.833
SVMnl-RFEl
Confusion matrices
PHT 63.2 1.2 0.2 0 35 1 0 0
B-PA 10.6 10.8 1.6 1.2 4 5 4 0
Wild-type KCNJ5 2.8 3.6 6.6 1.6 2 1 4 1
Variant KCNJ5 1.2 0.2 0.2 8.8 0 0 0 6
Diagnostic
performancec
Sensitivity, % 98 (97-98) 45 (43-47) 45 (42-49) 85 (81-88) 97 38 50 100
Specificity, % 70 (69-73) 94 (94-95) 98 (88-98) 97 (96-97) 78 96 93 98
AUROC 0.841 (0.831-0.850) 0.695 (0.684-0.706) 0.716 (0.700-0.736) 0.909 (0.890-0.920) 0.875 0.672 0.714 0.991
PPV, % 81 (80-83) 69 (67-71) 78 (74-81) 77 (74-80) 85 71 50 86
NPV, % 95 (94-95) 86 (85-87) 92 (91-93) 98 (97-99) 95 86 93 100
F score 0.888 (0.883-0.895) 0.537 (0.516-0.556) 0.562 (0.528-0.593) 0.801 (0.777-0.825) 0.909 0.500 0.500 0.923
Abbreviations: AUROC, area under the receiver operating characteristic curve; B-PA,
bilateral primary aldosteronism; NPV, negative predictive value; PHT, primary
hypertension; PPV, positive predictive value.
a For learning series, numbers in confusion matrices reflect 5-folds of patients (ie,
569/5 = 114 patient for each fold) with evaluations of each fold performed 10 times
within each learning series (thus, numbers represent the mean of 50 confusion
matrices).
b For the external validation series numbers reflect the learning proportions (90:10) and
10% (63) of the total number of patients (632) in the analysis.
c Values for diagnostic performance in learning series are shown with 95% CI, whereas
those for validation series are not.
JAMA Network Open | Pathology and Laboratory Medicine Steroid Profiling and Machine Learning for Diagnosing Primary Aldosteronism
JAMA Network Open. 2020;3(9):e2016209. doi:10.1001/jamanetworkopen.2020.16209 (Reprinted) September 29, 2020 8/14
jamanetwork/2020/jno/09_29_2020/zoi200603 PAGE: 8 SESS: 28 OUTPUT: Sep 9 7:50 2020
for external validation), which was particularly important for the limited population of 58 patients
with variant KCNJ5 APAs. Thus, measures of diagnostic performance for the SVM model of both
learning and external validation series, but particularly the latter, showed improvement as the
learning ratio increased from 50% to 90% (eFigure 11 in the Supplement). For the RF model, for
which population sizes of PA and hypertensive groups were both relatively large, measures of
diagnostic performance showed little difference between learning and validation series until the
learning ratio reached 90% (eFigure 12 in the Supplement).
Discussion
To our knowledge, this study is the first to demonstrate the application of multidimensional pattern
recognition and machine learning for analysis of steroidomic data in the diagnosis of PA. This
approach offers the potential for more efficient and effective diagnostic stratification than the
traditional series of multiple studies involving single end-point measures in relation to given cutoff
values. Stratification was achieved by distinct steroid profiles among subgroups of patients with PA.
From those profiles, panels of steroids were identified that can facilitate diagnosis of PA and, in the
same screening step, identify patients with variant KCNJ5 APAs for triaging as candidates likely to
show beneficial therapeutic outcomes from further interventions.
Among the steroids in the panel with distinctive profiles, 18-oxocortisol and 18-hydroxycortisol
stood out from the others for identifying patients with unilateral APAs due to somatic KCNJ5
sequence variants and were consistently among the top 4 steroids selected by machine-learning
algorithms. Previous studies have identified those hybrid steroids to be produced in excess in some
patients with PA,32-36 but only recently has it been clarified that elevations of these steroids are
linked to APAs with sequence variants of KCNJ5.23,37,38 The 2 hybrid steroids appear to be formed by
actions of aldosterone synthase on 11-deoxycortisol,39 which is normally produced in the zona
fasciculata and converted there to cortisol by 11β-hydroxylase. Production of the hybrid steroids by
variant KCNJ5 APAs is explained by their zona fasciculata phenotype and their expression of both
CYP11B1 and CYP11B2.40
The benefits of AVS over imaging to establish unilateral PA are well established.41 Nevertheless,
the originally suggested high diagnostic accuracy of AVS for indicating unilateral disease42 has not
been supported by some subsequent studies involving postadrenalectomy follow-up.14,15 In the
present study, the 88.5% postadrenalectomy biochemical cure rate lies between those found
previously29,41,43 and is similar to that found in a single prospective study.14 The failure of
adrenalectomy to cure PA may reflect asymmetric bilateral disease in some patients.44 Aldosterone-
producing cell clusters have been identified in the zona glomerulosa of aging adrenal glands and in
the adrenal glands of patients with PA due to bilateral adrenal aldosterone hypersecretion; in both
cases, cells of those clusters are characterized by high rates of sequence variants of CACNAID, but not
KCNJ5.45,46 This raises the possibility that KCNJ5 sequence variants might be characteristic of
unilateral adenomas. Nevertheless, 2 of our patients with variant KCNJ5 adenomas did not
experience complete biochemical cure after adrenalectomy, suggesting that KCNJ5 sequence
variants are not strictly associated with unilateral disease. Nevertheless, failure to reach cure in the
KCNJ5 sequence variant group was rare, confirming findings that patients with variant KCNJ5
adenomas show more clinical benefit after adrenalectomy than others.25-27 As we further establish
here, the benefit in terms of biochemical cure is independent of age and sex, further highlighting the
importance of triaging patients with variant KCNJ5 APAs for further interventions.
There have been other studies that combined steroid profiling with machine learning,47,48 but,
to our knowledge, this is the first to apply a combinatorial marker design strategy to PA. The potential
benefits for diagnostic stratification of PA are multiple. First, during screening it may be possible to
more effectively distinguish patients with PA from those with other causes of hypertension. Second,
by identifying within the same screening step patients with unilateral APAs due to KCNJ5 sequence
variants, it should be possible to immediately triage those patients for AVS; alternatively, with clear
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imaging evidence of a unilateral adenoma, it may be possible to directly proceed to an adrenalectomy
without AVS. These considerations underscore the potential advantages of moving away from
traditional unidimensional approaches (eg, ARR) for diagnostic stratification to multidimensional
approaches that take advantage of today’s computational power for applications of artificial
intelligence.
Limitations
As detailed in eAppendix 3 in the Supplement, the present analysis has limitations that are typical of
retrospective diagnostic studies, including dependence on traditional methods to establish patient
classifications. It thus cannot be guaranteed that PA was excluded in all patients designated as having
primary hypertension or that some cases of bilateral PA were incorrectly classified. Although patient
follow-up ensured that final cases of unilateral PA were correctly classified, reliance on Sanger
sequencing for identifying KCNJ5 sequence variants is not 100% sensitive; it is, thus, possible that
some wild-type KCNJ5 cases may have been incorrectly classified. Measurements of the ARR at
sampling time points different from those used for steroid profiling, batch effects, and
inconsistencies in supine and seated blood sampling represent other limitations. Seated sampling,
which increases plasma renin and aldosterone, likely accounts for the higher levels of aldosterone
and 18-oxocortisol in patients with PHT who were screened for PA compared with those of the
reference hypertensive population, for whom sampling was performed with patients in the supine
position. As outlined in the eAppendix 3 in the Supplement, because sampling for steroid profiles
among patients with PA was mainly performed with patients in the supine position, this may have
adversely impacted the performance of steroid profiles for distinguishing patients with PA from
those with PHT.
Conclusions
These findings suggest that plasma steroid profiles obtained during initial screening for PA can
improve case detection beyond that possible using the ARR alone. Moreover, the use of distinctive
profiles to identify patients with unilateral variant KCNJ5 APAs further illustrates the potential of
steroid profiling for disease stratification at a single screening step. Along with advances in functional
imaging49-51 and other measurements, such as the angiotensin peptidome,52,53 steroid profiling
combined with machine learning may facilitate more rapid identification of patients with PA for
appropriate therapeutic interventions. As detailed in eAppendix 3 in the Supplement, such strategies
are now being tested in further patient populations, and with those developments it may become
possible to screen more than the small proportion of patients with PA who are currently tested and
treated according to disease subtype.
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